Recently, WixBio ND-AI-IBH Vaccine (Newcastle Disease, Influenza, and Adenovirus Triple Vaccine), an inactivated poultry vaccine, was successfully shipped to the Middle East. This cooperation marks another important milestone for Wixbio in the international veterinary market and provides a powerful disease-prevention solution for the local poultry farming industry.
Product Advantages and Features
Based on advanced cell suspension culture and prokaryotic expression technologies, the new vaccine is characterized by its high antigenic content, long immunity period, and broad applicability. Integrating the prevention of three major poultry diseases in a single dose not only simplifies the immunization procedure but also effectively reduces the stress caused by multiple chicken vaccinations. In addition, the scientifically designed immunization program ensures adequate protection for chickens of different age groups, which helps to improve the farm’s overall production performance.
A new chapter of international cooperation
With the successful delivery of this batch of vaccines, Wixbio will further strengthen its partnership with its Middle East distributors in a joint effort to improve animal healthcare in the region. In response to the unique needs of the Middle East market, the company will continue to provide technical support and service guarantees to ensure the best use of vaccines in the region. At the same time, this also reflects Wixbio’s firm commitment to actively expanding overseas markets and serving global customers.
Wide Market Prospects
The widespread spread of H9 subtype avian influenza and Group I 4 avian adenovirus among poultry has caused significant economic losses to the poultry industry in recent years. Launching the new triple inactivated influenza adenovirus vaccine is effective in controlling the outbreak of these diseases, but also saves costs and improves economic efficiency for farmers. Wixbio’s new vaccine is expected to occupy a more important position in the international market in the coming years as more countries and regions recognize the product.
Wixbio will continue to focus on the industry’s development and introduce innovative veterinary biologics to contribute to the healthy development of the global livestock industry.
